ClinicalTrials.gg
CompletedNCT02006485Updated Nov 5, 2019

Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

A Phase 1 interventional study of Ublituximab + TGR-1202 and Ublituximab + TGR-1202 + ibrutinib in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma, sponsored by TG Therapeutics, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-05.

Sponsored by TG Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. ublituximab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
3rd of 13
160 · median 51
Started
2013
the only one that year
Phase 1
3 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
10 of 13
TG Therapeutics, Inc.

Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 3rd largest by enrollment, is the only one that started in 2013, is one of 3 in phase 1, and was the 4th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About ublituximab

ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed B-cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and other B-cell lymphoproliferative disorders as approved by the Medical Monitor or Study Chair
  • to or relapsed after at least 1 prior treatment regimen
  • (ECOG) score of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Any major surgery, chemotherapy or immunotherapy within the last 21 days
  • Known virus, virus or infection
  • Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months
  • Primary central nervous system lymphoma or known intracranial involvement
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Ublituximab + TGR-1202

    Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose

    Drug: Ublituximab + TGR-1202

  • Experimental
    Ublituximab + TGR-1202 + ibrutinib

    Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose ibrutinib oral daily dose

    Drug: Ublituximab + TGR-1202 + ibrutinib

  • Experimental
    Ublituximab + TGR-1202 + bendamustine

    Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Bendamustine at a fixed IV infusion on Days 1 \& 2

    Drug: Ublituximab + TGR-1202 + bendamustine

Interventions

  • DrugUblituximab + TGR-1202

    Drug pages: Ublituximab · Umbralisib

    Ublituximab IV infusion TGR-1202 oral daily dose

  • DrugUblituximab + TGR-1202 + ibrutinib

    Drug pages: Ublituximab · Umbralisib · Ibrutinib

    Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose

    Also known as: Imbruvica

  • DrugUblituximab + TGR-1202 + bendamustine

    Drug pages: Ublituximab · Umbralisib · Bendamustine

    Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion

    Also known as: Treanda

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose acceptable for participants

    To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities

    Time frame: 28 days (1 cycle of therapy)

Secondary outcomes

  1. Overall Response Rate

    To assess the overall response rate (ORR) in patients with hematologic malignancies treated with Ublituximab in combination with TGR-1202

    Time frame: Up to 1 year

07

Study locations

6 sites
  • TG Therapeutics Investigational Trial Site
    Huntsville, Alabama 35805, United States
  • TG Therapeutics Investigational Trial Site
    Jonesboro, Arkansas 72401, United States
  • TG Therapeutics Investigational Trial Site
    Duarte, California 91010, United States
  • TG Therapeutics Investigational Trial Site
    Atlanta, Georgia 30322, United States
  • TG Therapeutics Investigational Trial Site
    Omaha, Nebraska 68198, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Publications

  • Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 Nov 21;134(21):1811-1820. doi: 10.1182/blood.2019002118. PubMed 31558467 ↗
  • Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3. PubMed 30709431 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Oct 2019, 70 months.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 70 months is above that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2013
First posted
Dec 10, 2013
StartActual
Dec 13, 2013
Primary completionActual
Oct 2019
CompletionActual
Oct 2019
Last update
Nov 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02006485
Responsible party
Sponsor
First posted
Dec 10, 2013
Start date
Dec 13, 2013
Primary completion
Oct 2019
Completion
Oct 2019
Last update
Nov 5, 2019

Study contacts

Nathan Fowler, MD
study chair · M.D. Anderson Cancer Center
Susan O'Brien, MD
study chair · University of California Irvine Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ublituximab · Umbralisib · Ibrutinib · Bendamustine

Start the discussion